Skip to main content

Table 2 Prime-boost immunization trials against parasites

From: DNA vaccines: designing strategies against parasitic infections

Parasite Antigen Priming agent Boosting agent Response Reference
Malaria Circumsporozoite protein of P. berghei Attenuated fowlpox virus or DNA MVA Potent CD8+ T cell responses were elicited in mice with FPV/MVA vaccination. Novel regimen was more protective against challenge than DNA-MVA immunizations. [7]
  P. falciparum surface protein (Pfs25) DNA Recombinant protein Intramuscular injections in rhesus monkeys showed significant increase in transmission blocking antibodies. [8]
  Circumsporozoite protein of P. yoelii DNA Pox virus Immunized neonatal mice showed 93% protection which was CD8+ T cell dependent. [9]
  P. falciparum erythrocyte binding protein DNA Recombinant protein Higher antibody titers and the ability to reduce parasitemia without drug intervention in Aotus monkeys. [10]
  Circumsporozoite protein of P. falciparum DNA RTS, S/ASOZA Malaria volunteers develop P. falciparum specific Abs and Th1 specific CD4+ and CD8+ T cells upon vaccination. [11]
Leishmania Leishmania infantum LACK DNA Recombinant vaccinia virus 60% protection, associated with cell mediated responses, was observed in dogs after challenge compared to controls. [12]
  p36/LACK DNA Recombinant vaccinia virus Vaccination in mice resulted in 70% reduction in lesion size and 1000-fold reduction in parasite loads. [13]
  L. infantum acidic ribosomal protein PO (LiPO) DNA Recombinant protein Boosting elicited stronger IgG2a titers but could not protect against challenge compared to DNA alone. [14]
Schistosome Cu/Zn cytosolic superoxide dismutase (SOD), signal peptide SOD and glutathione peroxidase (GP) DNA MVA DNA vaccines were tested against S. masoni challenge in mice. Boosting with MVA for the same genes had no increased effect expect for mutated GP antigen were boosting lead to 85 % protection. [15]
Back to article page

Genetic Vaccines and Therapy

ISSN: 1479-0556